NGL Fine-Chem Limited - Asset Resilience Ratio
NGL Fine-Chem Limited (NGLFINE) has an Asset Resilience Ratio of 7.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NGL Fine-Chem Limited (NGLFINE) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2026)
This chart shows how NGL Fine-Chem Limited's Asset Resilience Ratio has changed over time. See NGL Fine-Chem Limited net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down NGL Fine-Chem Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NGL Fine-Chem Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs391.88 Million | 7.18% |
| Total Liquid Assets | Rs391.88 Million | 7.18% |
Asset Resilience Insights
- Limited Liquidity: NGL Fine-Chem Limited maintains only 7.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NGL Fine-Chem Limited Industry Peers by Asset Resilience Ratio
Compare NGL Fine-Chem Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 1.58% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for NGL Fine-Chem Limited (2013–2026)
The table below shows the annual Asset Resilience Ratio data for NGL Fine-Chem Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 7.18% | Rs391.88 Million ≈ $4.24 Million |
Rs5.45 Billion ≈ $58.99 Million |
-6.58pp |
| 2025-03-31 | 13.77% | Rs596.64 Million ≈ $6.45 Million |
Rs4.33 Billion ≈ $46.87 Million |
-1.68pp |
| 2024-03-31 | 15.45% | Rs549.19 Million ≈ $5.94 Million |
Rs3.56 Billion ≈ $38.45 Million |
-0.11pp |
| 2023-03-31 | 15.56% | Rs446.74 Million ≈ $4.83 Million |
Rs2.87 Billion ≈ $31.05 Million |
+5.12pp |
| 2022-03-31 | 10.44% | Rs289.05 Million ≈ $3.13 Million |
Rs2.77 Billion ≈ $29.95 Million |
-4.84pp |
| 2021-03-31 | 15.28% | Rs317.47 Million ≈ $3.43 Million |
Rs2.08 Billion ≈ $22.47 Million |
+6.07pp |
| 2020-03-31 | 9.21% | Rs141.50 Million ≈ $1.53 Million |
Rs1.54 Billion ≈ $16.61 Million |
+0.48pp |
| 2019-03-31 | 8.74% | Rs124.21 Million ≈ $1.34 Million |
Rs1.42 Billion ≈ $15.38 Million |
+1.34pp |
| 2018-03-31 | 7.40% | Rs95.61 Million ≈ $1.03 Million |
Rs1.29 Billion ≈ $13.98 Million |
+2.41pp |
| 2017-03-31 | 4.98% | Rs50.44 Million ≈ $545.44K |
Rs1.01 Billion ≈ $10.95 Million |
+0.97pp |
| 2016-03-31 | 4.01% | Rs31.10 Million ≈ $336.33K |
Rs775.06 Million ≈ $8.38 Million |
+0.89pp |
| 2015-03-31 | 3.12% | Rs20.74 Million ≈ $224.29K |
Rs665.17 Million ≈ $7.19 Million |
+2.38pp |
| 2014-03-31 | 0.74% | Rs4.15 Million ≈ $44.86K |
Rs558.46 Million ≈ $6.04 Million |
+0.65pp |
| 2013-03-31 | 0.09% | Rs424.10K ≈ $4.59K |
Rs473.96 Million ≈ $5.13 Million |
-- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more